NCT00723957 - A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

August 31, 2011

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

Ixabepilone, 32 mg/m^2

Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2

DRUG

Paclitaxel, 200 mg/m^2

IV solutions, paclitaxel, 200 mg/m\^2

DRUG

Carboplatin (area under the concentration curve [AUC] 6)

Carboplatin (AUC 6) day 1, every 21 days, 6 cycles

Trial Locations (33)

112

Local Institution, Taipei

333

Local Institution, Taoyuan Hsien

1425

Local Institution, Capital Federal

1437

Local Institution, Capital Federal

2200

Local Institution, Bankstown

3199

Local Institution, Frankston

6009

Local Institution, Nedlands

16132

Local Institution, Genova

20133

Local Institution, Milan

21201

Uof Md,Greenebaum Cancer Ctr., Baltimore

22927

Local Institution, Großhansdorf

23100

Local Institution, Sondrio

48903

Local Institution, Baracaldo (Vizcaya)

67085

Local Institution, Strasbourg

67090

Local Institution, Strasbourg

86021

Local Institution, Poitiers

89081

Local Institution, Ulm

90237

Scripps Cancer Center, La Jolla

99437

Local Institution, Bad Berka

129128

Local Institution, Moscow

194291

Local Institution, Saint Petersburg

198255

Local Institution, Saint Petersburg

390011

Local Institution, Ryazan

420029

Local Institution, Kazan'

454087

Local Institution, Chelyabinsk

C1426ANZ

Local Institution, Buenos Aires

05100

Local Institution, Terni

115 478

Local Institution, Moscow

411-769

Local Institution, Goyang-si

120-752

Local Institution, Seoul

135-710

Local Institution, Seoul

138-736

Local Institution, Seoul

407.5

Local Institution, Taichung